Three-year serologic immunity against canine parvovirus type 2 and canine adenovirus type 2 in dogs vaccinated with a canine combination vaccine.
A group of client-owned dogs and a group of dogs at a commercial kennel were evaluated for duration of antibody responses against canine parvovirus type 2 (CPV-2) and canine adenovirus type 1 (CAV-1) after receiving a combination vaccine containing recombinant canarypox-vectored canine distemper virus (CDV) and modified-live CPV-2, CAV-2, and canine parainfluenza virus, with (C6) or without (C4) two serovars of Leptospira (Recombitek C4 or C6, Merial). Duration of antibody, which correlates with protective immunity, was found to be at least 36 months in both groups. Recombitek combination vaccines can confidently be given every 3 years with assurance of protection in immunocompetent dogs against CPV-2 and CAV-1 as well as CDV. This allows this combination vaccine, like other, similar modified- live virus combination products containing CDV, CAV-2, and CPV-2, to be administered in accordance with the recommendations of the American Animal Hospital Association Canine Vaccine Task Force.
Larson
L J
LJ
Department of Pathological Sciences, University of Wisconsin, Madison, WI 53706-1102, USA.
Schultz
R D
RD
D000257:Adenoviridae Infections / Q000517:prevention & control / Q000662:veterinary*; D006516:Adenoviruses, Canine / Q000276:immunology*; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D004283:Dog Diseases / Q000097:blood / Q000517:prevention & control* / Q000821:virology; D004285:Dogs; D010322:Parvoviridae Infections / Q000517:prevention & control / Q000662:veterinary*; D017993:Parvovirus, Canine / Q000276:immunology*; D016896:Treatment Outcome; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000627:therapeutic use; D014765:Viral Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*
D000914:Antibodies, Viral; D017778:Vaccines, Combined; D014765:Viral Vaccines